## CLAIMS

We claim:

1. An injectable pharmaceutical composition comprising tetrahydrocannabinol, ethanol, water, and a pharmaceutically acceptable amphiphilic excipient.

2. A composition according to claim 1 further comprising a pharmaceutically acceptable excipient salt.

3. A composition according to claim 1 further comprising a pharmaceutically acceptable excipient oil.

4. A composition according to claim 1 further comprising a pharmaceutically acceptable excipient antioxidant.

5. A composition according to claim 1, wherein the concentration of tetrahydrocannabinol is, by mass, not greater than about 0.35%.

6. A composition according to claim 1, wherein the concentration of ethanol is, by mass, not greater than about 15%.

7. A composition according to claim 1, wherein the concentration of water is, by mass, not greater than about 90%.

8. A composition according to claim 1, wherein the amphiphilic excipient comprises at least one member of the group consisting of: Cremophor EL, Polysorbate 80,

Poloxamer 407, Poloxamer 237, PEG 400, Pharmasolve, propylene glycol, and hydroxypropyl beta-cyclodextrin.

9. A composition according to claim 2, wherein the salt comprises sodium chloride or sodium hydroxide.

10. A composition according to claim 3, wherein the oil comprises corn oil.

11. A composition according to claim 4, wherein the antioxidant comprises sodium metabisulfite or ascorbyl palmitate.

12. A composition according to claim 8, wherein the concentration of Cremophor EL is, by mass, not greater than about 20%.

13. A composition according to claim 8, wherein the concentration of Polysorbate 80 is, by mass, not greater than about 15%.

14. A composition according to claim 8, wherein the concentration of Poloxamer 407 is, by mass, not greater than about 2.5%.

15. A composition according to claim 8, wherein the concentration of Poloxamer 237 is, by mass, not greater than about 5%.

16. A composition according to claim 8, wherein the concentration of PEG 400 is, by mass, not greater than about 20%.

17. A composition according to claim 8, wherein the concentration of Pharmasolve is, by volume, not greater than about 10%.

18. A composition according to claim 8, wherein the concentration of propylene glycol is, by mass, not greater than about 60%.

19. A composition according to claim 8, wherein the concentration of hyroxypropyl beta-cyclodextrin is, by mass, not greater than about 30%.

20. A composition according to claim 9, wherein the concentration of the salt renders the composition essentially isotonic.

21. A composition according to claim 9, wherein the concentration of sodium chloride is, by mass, about 0.9%.

22. A composition according to claim 10, wherein the concentration of corn oil is, by mass, not greater than about 10%.

23. A method for manufacture of an injectable pharmaceutical composition comprising tetrahydrocannabinol, ethanol, water, and a pharmaceutically acceptable amphiphilic excipient, said method comprising the steps of: admixing tetrahydrocannabinol with ethanol to form a first mixture; admixing water with a pharmaceutically acceptable amphiphilic excipient to form a second mixture; and

admixing the first mixture with the second mixture to form a third mixture, wherein said third mixture comprises an intermediate or a finished product in the manufacture of the injectable pharmaceutical composition.

24. A method of treating, lessening, or ameliorating emesis, anorexia, or chronic or AIDS-related wasting syndrome in a subject in which it is desired to treat, to lessen, or to ameliorate emesis, anorexia, or chronic or AIDS-related wasting syndrome, said method comprising administering to the subject a therapeutically effective amount of a composition according to claim 1.